| |
|
|
|
| Personalized Psychiatry? Psychiatry is unique among medical disciplines:Poor understanding of disease biologyLack of objective diagnostic and follow-up tools |
|
|
|
|
| Pharmacogenetics . Inherited disorders whose manifestations are enhanced or inducedMHClassic Presentation . Hypermetabolism; Tachycardia; Tachypnea; Hypercarbia; Hypoxia |
|
|
|
|
| Pharmacogenetics/Pharmacogenomics . Objectives: Genetic information, including the sequence of the human genome, is allowing for a more systematic understanding of the |
|
|
|
|
| ADVERSE EFFECTS TO SULFASALAZINE IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE. Data from: Das et al. N Engl J Med 289:491-495, 1973. Side Effect. cyanosis ... |
|
|
|
|
| Renal Cell Carcinoma/Ovarian Cancer. Promising activity. Breast Cancer. E2100 ASCO 2005. Stratify:. DFI < 24 mos. vs. > 24 mos. < 3 vs. ... |
|
|
|
|
| from gene to therapy. Prof Jean-Pierre Hugot. Hopital Robert Debré Gene therapy (in the future?) Pharmacogenetics; Drug discovery (disease mechanisms) |
|
|
|
|
| Review the concept of pharmacogenetics and pharmacogenomics; Discuss how genetics and the environment affects the activity of drug metabolizing enzymes and transporters |
|
|
|
|
| Alpha-1-Antitrypsin DeficiencyAlpha 1-antitrypsin (A1AT) is a serine protease inhibitor. Its main function is to inhibit the action of proteases e.g. elastase produced by |
|
|
|
|
| Resistance detected to all clinically relevant antibiotics; Resistance mechanisms conferred by chromosomal mutations/changes or more commonly, |
|
|
|
|
| Baird, P.A. (1994) Altering human genes: Social, ethical, and legal implications. Perspectives in Biology and Medicine 37, 566-575. …www.tekno.dk/Tekvaerket/konference2001/Bioteknologikonference.ppt |
|
|
